We report the identification of Schlafen Family Member 11 (SLFN11) mRNA level as a biomarker predictive of response to chemotherapeutics, including topoisomerase inhibitors, alkylating agents, anti-metabolites, and anti-tumor anti-biotics in solid tumor lineages. This evidence concerns the gene SLFN11 and neoplasm.